Xcout IntelSign inSubscribe

Intelligent Bio Solutions Inc.

INBSMedical DevicesNew York City, NY, United States

Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Subscribe to see Intelligent Bio Solutions Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

Intelligent Bio Solutions Inc. at a glance

Intelligent Bio Solutions Inc. is a medical devices company headquartered in New York City, United States. It is publicly listed (INBS) with a market capitalisation of $6.4M. Xcout tracks 17 named people at Intelligent Bio Solutions Inc., including Harry Simeonidis (President & Chief Executive Officer).

As of 16 November 2026. Source: Xcout Intel.

Industry
Medical Devices
Headquarters
New York City, NY, United States
Market cap
$6.4M
Employees
50
Ticker
INBS

Intelligent Bio Solutions Inc. leadership

  • Harry SimeonidisPresident & Chief Executive Officer
  • Spiro Kevin SakirisChief Financial Officer
  • Spiro SakirisChief Financial Officer
  • Anna TurkingtonVice President of Marketing
  • Callistus SequeiraVice President of Global Quality & Operations
  • Doug HeathVice President of Global Sales

11 more named people on record for Intelligent Bio Solutions Inc., with roles, board committees and tenure — see the full roster →

Who owns Intelligent Bio Solutions Inc.

8 institutions reported a position for the quarter ending 30 June 2026, and 7 insiders hold at least 0.1% of the shares.

Armistice Capital: 4.70%Spiro Kevin Sakiris: 1.20%Harry Simeonidis: 1.10%Geode Capital: 0.70%Christopher Towers: 0.30%Other institutions: 0.60%Other insiders: 0.70%Not held by 13F institutions or listed insiders: 90.70%Intelligent Bio S…6.0%held byinstitutions
Ownership of Intelligent Bio Solutions Inc. by 13F institution and insider
Holder% of shares outstanding
Armistice Capital4.70%
Spiro Kevin Sakiris1.20%
Harry Simeonidis1.10%
Geode Capital0.70%
Christopher Towers0.30%
Other institutions0.60%
Other insiders0.70%
Not held by 13F institutions or listed insiders90.70%
  1. 1Armistice CapitalARMISTICE CAPITAL, LLC4.7%
  2. 2Spiro Kevin SakirisIndividualChief Financial OfficerFiled as Sakiris Spiro Kevin · 20 Mar 20261.2%
  3. 3Harry SimeonidisIndividualChief Executive OfficerFiled as Simeonidis Harry · 20 Mar 20261.1%
  4. 4Geode CapitalGEODE CAPITAL MANAGEMENT, LLC0.7%
  5. 5Christopher TowersIndividualDirectorFiled as TOWERS CHRISTOPHER · 6 Oct 20230.3%

The full list of 8 institutions, with share counts and what each bought or sold since the previous quarter.

Sign in to see it, or subscribe →

Source: SEC Form 13F filings, period ending 30 June 2026; shares outstanding from the company's 10-K/A as of 18 August 2026. 13F covers the US-listed holdings of investment managers with more than $100 million under management and is filed up to 45 days after the quarter ends. A firm that files under several names (Vanguard files as two managers) is one row, with its filers listed under it. Individuals are company insiders (directors, officers and 10% owners) holding at least 0.1% of the shares, from their latest SEC Form 3, 4 or 5 (newest 20 March 2026), counting shares held directly and through trusts and other entities they report, including high-vote class shares (such as Class B); options and restricted stock units are not counted. They are a separate slice from the 13F institutions, so the ring adds up to 100%: what is left is held by smaller insiders, retail investors and anyone else who does not file.

Intelligent Bio Solutions Inc. competitors

A few of Intelligent Bio Solutions Inc.'s closest competitors — see the full list of competitors and alternatives →

Get Intelligent Bio Solutions Inc.'s news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Something wrong or missing about Intelligent Bio Solutions Inc.? Suggest a correction · Work at Intelligent Bio Solutions Inc.? Claim this profile

Is this your company? Add the Xcout Intel badge to your website

Free, for any company on Xcout Intel. It links visitors to this profile.

Intelligent Bio Solutions Inc. on Xcout Intel

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

Intelligent Bio Solutions Inc. — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on Intelligent Bio Solutions Inc. in Xcout Intel

  • 17 named people with titles, LinkedIn and board committees
  • 4 corporate events with sources — deals, leadership changes, layoffs
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →